drugset
drugset / Trial / NCT07294209

Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients

NCT07294209 ↗

Phase 4 Recruiting 798 enrolled Southwest Hospital, China
RandomizedParallel-groupSingle-blindTreatment

Summary

The DATE-AGING study is a prospective, multicenter, randomized controlled trial investigating low-dose tenecteplase in elderly patients with acute ischemic stroke. Its primary objective is to evaluate the safety and efficacy of low-dose tenecteplase in elderly patients within 4.5 hours of acute ischemic stroke onset.

Timeline

Start
2025-12-19
Primary completion
2028-12-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenecteplase Protein / enzyme biologic 0.175 mg/kg Intravenous
Subject Tenecteplase Protein / enzyme biologic 0.25 mg/kg Intravenous

Indications

stroke disorder